Introduction
Long before any objective recording could be applied, there was already the belief that sleep has a restorative function. Since the discovery by Loomis et al.' that during sleep different states appear which are characterized by separate and distinct EEG patterns, sleep research has grown continuously. This led to the identification and standardization of the sleep stage classification based on EEG and non-EEG parameters (muscle tone, eye movements) by Rechtschaffen and Kales2. Indeed, sleep is not a simple, passive and uniformly progressive decrease of activity. Two sleep states were recognized and by convention designated as REM sleep (rapid eye movement sleep or active sleep) and non-REM (NREM) sleep. NREM sleep is further divided into 4 stages during which sleep progressively deepens: NREM stages 1 and 2 are termed light slow-wave sleep (SWS) and NREM stages 3 and 4 are termed deep SWS.
Not all stages of sleep are equally important. In this respect, Adam and Oswald3 defined that sleep with large EEG slow waves is 'worth more' because of its restorative properties. Furthermore, Dement4 was the first to show that when sleep is deprived of especially REM, there appears to be a compensation for the sleep loss as soon as unbroken sleep is allowed; in the same way, selective deprivation of SWS leads to an increase in SWS afterwards5-'. So it seems that both types of sleep are needed, although several studies8'9 indicate marked declines in sleep duration (decreased SWS) and sleep quality through maturity and old age. Whether this phenomenon is physiological or pathological remains unclear.
As to sleep related to illness, and more particularly psychiatric illness, Hawkins et al.10 suggested that sleep may protect against depression and that if the individual sleep mechanisms work less well, the subject may be more susceptible to depression on the one hand, and attacks may be more severe on the other hand. In this context, it is stated that depression tends to be more frequent and more severe with aging9'1'. Acute and chronic schizophrenic patients have very low levels of deep SWS (NREM, Stage 4), a finding which has been confirmed repeatedly'2-4. Further evidence has recently been published by Hiatt et al." , reporting the preliminary results of an ongoing investigation in unmedicated schizophrenics. They demonstrated highly significant abnormalities in delta wave forms, illustrating the robust nature of the disturbance of NREM physiology in this illness: 'While not present in all schizophrenic patients, altered 0.5 to 3 Hz EEG may prove to be the most reliable (i.e. consistently present) brain abnormality yet described in this illness'. It was proposed"6 that NREM sleep is a correlate of a metabolic process that acts to reverse the effects of waking on the brain and that this process occurs at its highest rate during Stage 4. Thus evidence continues to accumulate on the relevance of SWS, especially in those subjects with 0141/0768/87/ 070409-05/$02.00/0 o 1987 The Royal Society of Medicine decreased amounts of delta sleep due to aging or in relation to affective states such as depression and schizophrenia.
Centrally acting serotonin-S2 receptor blockers: pharmacological picture A variety of neural and neurohumoral mechanisms and processes are thought to be implicated in the organization and regulation of sleep17. From what precedes, however, attempting to promote SWS would seem to be logical. A number of processes have been postulated in this respect.
Radulovacki et al. found that adenosine elevated SWS and reduced waking time in rats. Nicholson et al."9 stated that H,-antagonism may reduce wakefulness, H2-antagonism may increase slow-wave activity and that these effects imply a complementary role of the H, and H2 systems in the control of the sleep process. Inoue & Borbely20 reviewed the role of endogenous sleep substances, including a number of polypeptides.
Amongst the various neurotransmitters involved in sleep regulation, many experiments indicated 'that serotonergic transmission mechanisms are involved as active factors, or inducing processes, in the organization of sleep; i.e. that they constitute an important part of a putative sleep-organizing apparatus '2 The first report on the effect of L-tryptophan, the serotonin precursor, on REM sleep dates back to 196622. But it was Jouvet23 who first demonstrated in cats that the presence of serotonin is required for SWS. Since then, studies in rats24, rabbits25 and healthy human volunteers26 have been in agreement with these findings, supporting the theory of serotonergic mechanisms governing NREM sleep. So it seems well established that serotonin plays an important role as a sleep-inducer or as an anti-wake substance. However, in contrast, this concept has been challenged by observations in rats27 and human subjects28 showing little or no effect of serotonin depletion. In addition, Oswald et al. 29 reported on a mixed serotonin-dopamine antagonist and its ability selectively to increase human SWS. Furthermore, Jouvet neurotransmitter during wakefulness could act as a 'neurohormone' inducing hypnogenic factors responsible for SWS. Part of these controversies may be explained by the fact that the compounds studied possess mixed agonistic/antagonistic properties.
The discovery of ritanserin, therefore, can be considered a very important step forward in sleep/ serotonih research. Ritanserin is the first extremely potent, specific andpure serotonin-S2 antagonist that passes the blood-brain barrier easily. It belongs to a new series of chemically related compounds of which ketanserin, a peripherally acting 5-HT2 receptor antagonist under clinical investigation for cardiovascular diseases, is the prototype. From the receptor binding point of view31, the most remarkable feature of ritanserin is its high binding affinity for serotonin-S2 receptors. In rat frontal cortex, only 0.9 nmol concentration of ritanserin is needed to displace the ligand ketanserin from the receptor binding sites.
The IC50 values for binding to other sites (histamine-H1, dopamine-D2, a, and a2-adrenergic sites) are so much higher that they are of no pharmacological importance. The fact that ritanserin is devoid of any dopamine-D2 antagonism means that it is devoid of any neuroleptic activity.
Serotonin-S2 blockers: sleep promoters
Pharmacologically, ritanserin appears to be a very interesting drug. Its potency and the specificity of its serotonin-antagonistic effect make it a valuable tool for the study of the role played by serotonin in the mechanisms and structures of sleep. A first exploratory polygraphic sleep study in 4 volunteers has been undertaken by De Clerck in the Netherlands (in preparation). The results were very surprising: SWS increased, Stages 1 and 2 decreased. Moreover, subjects reported an improvement in sleep quality and sleep depth.
In a randomized placebo-controlled crossover sleep study in 9 subjects in Great Britain, 10 mg ritanserin given either in the morning or in the evening was compared with 5 mg nitrazepam32. The polygraphs were scored blind. As expected, nitrazepam reduced REM and SWS. Ritanserin again significantly increased SWS after both morning (+ 97%) and evening administration (+ 70%), the morning dose being significantly more potent than the evening dose (Figure 1 ). The significance of this doubling of SWS was observed on an individual basis. Ritanserin did not affect wakefulness or Stage 1 parameters or sleep onset latency.
A subsequent experiment, evaluating the effects of repeated doses, was designed to investigate whether the increase in SWS, noted after a single intake of ritanserin, was maintained over a two-week period33. Seven healthy male volunteers took 10 mg ritanserin each morming for 14 days and its effects on sleep were measured on the 1st, 7th, 13th and 14th night. Baseline data were collected on the two nights immediately prior to the start of ritanserin administration. Data on the sleep stages are given in Table 1 . The effects on sleep of a subehronic administration of ritanserin were found to be similar to those observed in the previous study after single doses. These findings have been confirmed in a subsequent double-blind placebo-controlled crossover study conducted by Clarenbach in Germany (personal communication). Ritanserin 10 mg administered over a 10-day period to 7 healthy male volunteers increased SWS to an important extent, whilst the latencies to Stage 2, Stages 3 & 4 and REM did not differ significantly from placebo.
Clinical applications of ritanserin
If the assumption that SWS is important because of its restorative function is true, beneficial effects from ritanserin treatment should be expected in patients with the following symptoms: sleep disturbances, chronic tiredness, feelings of inadequacy, decreased effectiveness, decreased attention, social withdrawal, loss of interest, irritability, inability to respond to praise or reward, decreased activity, and pessimism. There are at least two clinical situations in psychiatry in which these symptoms are present to a greater or lesser extent: in patients with 'dysthymic disorder', with their typical complaints of apathy, lack of drive, anxiety and depressive mood; and in chronic schizophrenic patients with anergy and predominantly negative symptoms.
The results of two recently completed studies on these indications seem to confirm the above assumptions:
Ninety-three patients suffering from dysthymic disorder with at least moderate symptomatology were randomly allocated to 10 mg ritanserin twice daily or matching placebo for 40 days (Hoppenbrouwers, in preparation). After only 10 days of therapy, a statistically significant intergroup difference in favour ofritanserin was noted for the clinical global impression. This superiority of ritanserin over placebo was maintained throughout the trial: 63% of the ritanserintreated patients had an excellent or good therapeutic effect,
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Moreover, the total Hamilton Depression Rating Scale, the individual items 'depressed mood', 'early insomnia', 'agitation', 'psychic anxiety' (Figure 2) , and the cluster 'retardation' composed of items strongly related to symptoms of anergy, improved to a marked extent with ritanserin. A comparison of the test medication with the most successful medication previously administered showed that 42% ofthe ritanserin-treated patients had more therapeutic Total negative symptoms PTR W6 PTR W6 PTR W6 PTR W6 Figure 4 . Mean (± s.e. mean) score ofthe total Brief Psychiatric Rating Scale (BPRS) and the negative symptoms before (PTR) and after 6 weeks (W6) of therapy with ritanserin (U) and placebo (O 00PTR W6 PTR W6 Figure 5 . Mean (+ s.e. mean) score of the total Simpson and Angus scale and of tremor before (PTR) and after 6 weeks (W6) of therapy with ritanserin (a) and placebo (O). (*P < 0.05, Wilcoxon matched-pairs signed-ranks test and Mann-Whitney Utest, two-tailed probability) benefit from ritanserin than from previous medications against only 9% in the placebo group. The incidence and severity of side effects did not differ between the two treatment groups.
Thirty-three predominantly Type II chronic schizophrenic patients were given either ritanserin at a fixed dose of 10 mg twice daily for six weeks or matching placebo as an add-on drug to an existing neuroleptic therapy (Gelders, in preparation). Although the neuroleptic maintenance treatment had been carefully and repeatedly adapted to obtain optimal improvement, the condition in the selected patients was not satisfactory with negative symptoms remaining prominent. In comparison with placebo, a significant improvement was observed with ritanserin for the clinical global impression (Figure 3 ), for the total Brief Psychiatric Rating Scale, and also for the clusters of the negative symptoms of this scale (Figure 4 ). The extrapyramidal symptoms of the Simpson and Angus Scale also improved significantly during ritanserin therapy, whereas they remained unchanged under placebo. Moreover, ritanserin reduced tremor significantly as compared to placebo ( Figure 5 ).
Discussion
Neurophysiological studies on human sleep have provided evidence of the drastic increases of SWS induced by the S2 antagonist ritanserin32 33. In addition, subjects reported an improvement in sleep quality and sleep depth. It is attractive to speculate that the increase of SWS might explain the increased level of energy observed in patients with a variety of psychiatric disturbances in whom symptoms of dysthymia are present. Ritanserin may help to restore energetic functions during the night, resulting in an improvement of a number of symptoms related to anergy and in normalization of affective states.
Ongoing clinicopharmacological studies in dysthymic and schizophrenic patients should provide us with the 'missing link' between ritanserin's effect on sleep and its clinically proven thymosthenic properties.
'Anyone who tries to develop new drugs for diseases of the nervous system is looking for a good way of going out of business.' Leo Hollister, 1962 Never before has the promise for therapeutic breakthroughs in psychiatry been greater. An explosion of knowledge in basic neurobiology, resulting in ever-increasing discoveries of new neurotransmitters and receptors, has generated the necessary momentum for psychopharmacology to apply its new information towards the development of novel and improved treatments for diseases of the nervous system. In order to capitalize upon the opportunities at hand, it is important to consider not only the basic needs of patients with mental disorders, but also the strategy by which the fruits ofthe basic science laboratories can best be brought to the bedside. Are drugs, in fact, at all necessary for the treatment of mental illness, and if so, where and how could innovations occur in psychopharmacology? Should new uses be found for old drugs or should entirely new chemical entities be developed? Furthermore, how can the full potential of any drug be best exploited (e.g. new technology)? With these questions in mind, this paper examines the status of current drug therapies in the major nervous system diseases, and attempts to foresee the direction future research could take in each of these areas. Finally, a 'wish list' is proposed for new drug development in the 21st century.
Are drugs necessary?
The problems drugs cause when abused by members of the general population, or when inappropriately prescribed by physicians, has given rise to the accusation that we are an 'overmedicated society". It has been suggested that alternatives to drug therapy should be sought, especially in the case of mental illnesses where this 'overmedication' is most likely to occur. One alternative to drug therapy could take the fonn of 'prescriptive' psychotherapies, where the needs of an individual would be matched to a variety of psychotherapy techniques rather than the current practice of having a single therapy which is applied to several psychological problems. Great strides are already being made in this area. Rather than using a technique such as family therapy for everything from anxiety to schizophrenia, a standardized psychotherapy, such as brief interpersonal therapy2 or cognitive therapy' is prescribed for individuals meeting specific selection criteria. Often, however, these techniques will not be potent enough or rapid enough to be truly beneficial to a patient, in which case drugs could be co-prescribed. The treatment of patients with mental illnesses may eventually be approached in the same manner that physicians now treat hypertension. Each patient's therapy could be individualized, based on a close examination oftheir lifestyle, habits, medical health, medical history, environmental influences and physical exercise. Thus, the solution appears not to be to see the issue as a question of drugs as opposed to other approaches, but rather to see drugs as possibly playing only a part in an all-encompassing therapy.
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